The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. It is expected that about 60 people will take part in this research study.~There are 3 study groups participating in this study and each group receives different study drugs. After screening, participants will be randomized into one of three study groups.~Participants will receive one of the following study treatments prior to undergoing surgery for tumor removal:~Group A receives nivolumab plus ipilimumab~Group B receives nivolumab plus placebo-ipilimumab~Group C receives two placebo infusions, placebo-nivolumab plus placebo-ipilimumab~Neither the participant nor the research doctor will know which study drugs the participant will receive prior to surgery.~After recovering from surgery, participants will receive doses of study medication based on the study group:~Group A receives nivolumab plus ipilimumab every 3 weeks for 3 doses followed by nivolumab every 4 weeks~Group B receives nivolumab every four weeks~Group C receives nivolumab plus ipilimumab every 3 weeks for 4 doses followed by nivolumab every 4 weeks~This research study is a Phase Ib clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. Investigational means the drug is being studied.~The U.S. Food and Drug Administration (FDA) has not approved the use of nivolumab or ipilimumab for your specific disease, but it has been approved for other uses.~Both nivolumab and ipilimumab are antibodies (types of human protein) that work to stop tumor cells from growing and multiplying by immunotherapy.~Immunotherapy is trying to have the body's own immune system work against tumor cells. Nivolumab and ipilimumab have been used in other research studies, and information from those other research studies suggest these drugs may help to stop glioblastoma cells from growing.~Subjects also have the option of undergoing 89Zr-Df-IAB22M2C PET scans. This consists of one infusion with 89Zr-Df-IAB22M2C followed by a PET scan prior to starting study treatment and another infusion with PET scan about 3 days prior to surgery.~The U.S. Food and Drug Administration (FDA) has not approved 89Zr-Df-IAB22M2C as a treatment for any disease.
This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma.~The names of the study drugs involved in this study are:~Nivolumab~Ipilimumab~Placebo (IV solution with no medicine)~89Zr-Df-IAB22M2C (optional sub-study)